IPO - Nok Therapeutics, Inc.

Form Type: CORRESP

Filing Date: 2024-12-30

Corporate Action: Ipo

Type: New

Accession Number: 000121390024113355

Filing Summary: NÖK Therapeutics, Inc. has submitted a request for the qualification of its Offering Statement on Form 1-A, which was originally filed on September 26, 2024. The company is seeking this qualification on or before January 3, 2025, or as soon as practical thereafter. The letter emphasizes the understanding that even if the SEC qualifies the filing, the agency retains the right to take action regarding the filing. It also highlights the company's accountability for the adequacy and accuracy of the disclosures made in the filing, stating that the SEC staff's comments or qualification cannot be used as a defense in any legal proceedings. The communication is signed by Robert Lewis, the President, CEO, and Director of NÖK Therapeutics, Inc.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-11-07

Corporate Action: Ipo

Type: Update

Accession Number: 000121390024095371

Filing Summary: NÖK Therapeutics, Inc. submitted a response to the SEC's comment letter regarding their Offering Statement on Form 1-A filed on September 26, 2024. Key revisions included removing business descriptions, detailing product candidates and development activities, and enhancing risk factors to ensure specificity. They also amended sections on dilution analysis and the plan of distribution to address fund return arrangements. Furthermore, clarifications were made regarding the terms of board members and employment disclosures of executive officers. Amendments were also made throughout the document to comply with SEC regulations, including the incorporation of the subscription agreement form and the legality opinion regarding share issuance.

Document Link: View Document